.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,262,169

« Back to Dashboard

Claims for Patent: 5,262,169

Title: Tablets and granulates containing mesna as active substance
Abstract:A granulate containing mesna is made by granulating mesna in the presence of an alcohol, acetone or a mixture of one of these with water. The granulate may be converted to tablets, along with other agents. The tablets contain: 0.01-1 parts by weight of a binding agent 0.03-0.4 parts by weight of a disintegrant 0.01-0.2 parts by weight of a lubricant and 0.1-1 parts by weight of a filling agent as well as, in the case of an effervescent tablet, an additional 0.05-30 parts by weight of a conventional physiologically acceptable effervescent mixture.
Inventor(s): Sauerbier; Dieter (Werter, DE), Engel; Jurgen (Alzenau, DE), Milsmann; Eckhard (Bielefeld, DE)
Assignee: Asta Medica Aktiengesellschaft (DE)
Application Number:07/730,178
Patent Claims: 1. A tablet comprising, as active ingredient, mesna in combination with, for each part by weight of mesna:

0.01-1 parts by weight of a binding agent selected from the group consisting of polyvinylpyrrolidone, gelatin and microcrystalline cellulose

0.03-0.4 parts by weight of a disintegrant selected from the group consisting of starch, cross-linked polyvinylpyrrolidone and bentonite

0.01-0.2 parts by weight of lubricant selected from the group consisting of stearates, talcum and polyglycols

0. 1-1 parts by weight of a filling agent selected from the group consisting of starch, cellulose, lactose, fructose, saccharose, sorbitol, mannitol, calcium phosphate and calcium hydrogen phosphate.

2. A tablet as set forth in claim 1 containing, in addition, at least one member of the group consisting of flavoring, sweetening and aromatizing substances.

3. A tablet according to claim 1 which contains 10-80 percent by weight of mesna.

4. A tablet according to claim 1 which is coated with a pharmaceutically-acceptable film.

5. A process for manufacture of a stable oral dosage form of mesna which contains, for each part by weight of mesna:

0.01-1 parts by weight of a binding agent selected from the group consisting of polyvinylpyrrolidone, gelatin and microcrystalline cellulose

0.03-0.4 arts by weight of a disintegrant selected from the group consisting of starch, crosslinked polyvinylpyrrolidone and bentonite

0.01-0.2 parts by weight of a lubricant selected from the group consisting of stearates, talcum and polyglycols

0.1-1 parts by weight of a filling agent selected from the group consisting of starch, cellulose, lactose, fructose, saccharose, sorbitol, mannitol, calcium phosphate and calcium hydrogen phosphate said process including the step of granulating the mesna with at least one member of the group consisting of C.sub.1 -C.sub.4 -alcohols, acetone and mixtures of these organic agents with water, together with at least a portion of said filling agent and at least a portion of said binding agent, and converting the resulting granulate into a stable oral dosage form of mesna.

6. A process as set forth in claim 5 in which there is present, during the granulation, a disintegrant.

7. A process as set forth in claim 5 including the step of drying the granulate thus formed.

8. A process as set forth in claim 7 including the step of combining the granulate thus formed with a lubricant.

9. A process as set forth in claim 7 or claim 8 including the step of pressing the granulate into tablets.

10. A process as set forth in claim 9 including the step of applying a pharmaceutically-acceptable coating to the tablet.

11. A process for the manufacture of a stable oral dosage form of mesna which consists essentially of, for each part by weight of mesna:

0.01-1 parts by weight of a binding agent selected from the group consisting of polyvinylpyrrolidone, gelatin and microcrystalline cellulose

0.03-0.4 parts by weight of a disintegrant selected from the group consisting of starch, crosslinked polyvinylpyrrolidone and bentonite

001-0.2 parts by weight of a lubricant selected from the group consisting f stearates, talcum and polyglycols

0.1-1 parts by weight of a filling agent selected from the group consisting of starch, cellulose, lactose, fructose, saccharose, sorbitol, mannitol, calcium phosphate and calcium hydrogen phosphate

said process including the step of granulating the mesna with at least one member of the group consisting of C.sub.1 -C.sub.4 -alcohols, acetone and mixtures of these organic agents with water, together with at least a portion of said filing agent and at least a portion of said binding agent, and converting the resulting granulate into a stable oral dosage form of mesna.

12. A process as set forth in claim 11 in which there is present, during the granulation, a disintegrant.

13. A process as set forth in claim 11 including the step of drying the granulate thus formed.

14. A process as set forth in claim 13 including the step of combining the granulate thus formed with a lubricant.

15. A process as set forth in claim 13 or claim 14 including the step of pressing the granulate into tablets.

16. A process as set forth in claim 15 including the step of applying a pharmaceutically-acceptable coating to the tablet.

17. A tablet consisting essentially of, as active ingredient, mesna in combination with, for each part by weight of mesna:

0.01-1 parts by weight of a binding agent selected from the group consisting of polyvinylpyrrolidone, gelatin and microcrystalline cellulose

0.03-0.4 parts by weight of a disintegrant selected from the group consisting of starch, cross-linked polyvinylpyrrolidone and bentonite

0.01-0.2 parts by weight of a lubricant selected from the group consisting of stearates, talcum and polyglycols

0.1-1 parts by weight of a filling agent selected from the group consisting of starch, cellulose, lactose, fructose, saccharose, sorbitol, mannitol, calcium phosphate and calcium hydrogen phosphate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc